Literature DB >> 16114976

Autoimmune bullous diseases: ocular manifestations and management.

Caroline Laforest1, Shyamala C Huilgol, Robert Casson, Dinesh Selva, Igal Leibovitch.   

Abstract

The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmune-induced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including methotrexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16114976     DOI: 10.2165/00003495-200565130-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  94 in total

Review 1.  Mucocutaneous features of autoimmune blistering diseases.

Authors:  M A Weinberg; M S Insler; R B Campen
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1997-11

2.  Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices.

Authors:  A G Secchi; M S Tognon
Journal:  Am J Ophthalmol       Date:  1996-11       Impact factor: 5.258

Review 3.  Cicatricial pemphigoid and erythema multiforme.

Authors:  B J Mondino
Journal:  Ophthalmology       Date:  1990-07       Impact factor: 12.079

4.  Severe ocular involvement in a patient with epidermolysis bullosa acquisita.

Authors:  P G Lang; M J Tapert
Journal:  J Am Acad Dermatol       Date:  1987-02       Impact factor: 11.527

5.  Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.

Authors:  M Megahed; S Schmiedeberg; J Becker; T Ruzicka
Journal:  J Am Acad Dermatol       Date:  2001-08       Impact factor: 11.527

Review 6.  Immunobullous diseases with ocular involvement.

Authors:  C Camisa; D M Meisler
Journal:  Dermatol Clin       Date:  1992-07       Impact factor: 3.478

7.  Immunosuppressive therapy for progressive ocular cicatricial pemphigoid.

Authors:  C S Foster; L A Wilson; M B Ekins
Journal:  Ophthalmology       Date:  1982-04       Impact factor: 12.079

8.  Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study.

Authors:  V A Venning; P A Frith; A J Bron; P R Millard; F Wojnarowska
Journal:  Br J Dermatol       Date:  1988-01       Impact factor: 9.302

9.  Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid.

Authors:  M J Elder; J K Dart; R Collin
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

10.  Conjunctival involvement in paraneoplastic pemphigus.

Authors:  S J Meyers; G A Varley; D M Meisler; C Camisa; A H Wander
Journal:  Am J Ophthalmol       Date:  1992-11-15       Impact factor: 5.258

View more
  8 in total

1.  Response of ocular pemphigus vulgaris to therapy. Case report and review of literature.

Authors:  Malgorzata Olszewska; Marta Komor; Magdalena Mazur; Tomasz Rogozinski
Journal:  J Dermatol Case Rep       Date:  2008-03-29

2.  Cicatricial changes in ocular pemphigus.

Authors:  P Chirinos-Saldaña; I Zuñiga-Gonzalez; J C Hernandez-Camarena; A Navas; T Ramirez-Luquin; A Robles-Contreras; M C Jimenez-Martinez; A Ramirez-Miranda; V M Bautista-de Lucio; E O Graue-Hernandez
Journal:  Eye (Lond)       Date:  2014-01-31       Impact factor: 3.775

Review 3.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

4.  Ocular involvement and blindness secondary to linear IgA dermatosis.

Authors:  Cinthya Ramos-Castellón; Gabriela Ortiz-Nieva; Fernando Fresán; Leonardo Villalvazo; Yonathan Garfias; Alejandro Navas; María C Jiménez-Martínez
Journal:  J Ophthalmol       Date:  2010-12-22       Impact factor: 1.909

5.  Recurrent corneal melting in the paraneoplastic pemphigus associated with Castleman's disease.

Authors:  Haijun Gong; Shiyou Zhou; Yuxin Hu; Yuqin Lan; Hong Zeng; Liangchun Wang; Qingyu Liu; Mei Wang
Journal:  BMC Ophthalmol       Date:  2016-07-12       Impact factor: 2.209

Review 6.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

7.  Ocular Involvement in Pemphigus Vulgaris Without Skin Lesions: A Case Report.

Authors:  Iyad Majid; Brandon R Martel; Melanie Martel; Leslie K Tamura
Journal:  Cureus       Date:  2022-06-24

8.  Paraneoplastic pemphigus: a paraneoplastic autoimmune multiorgan syndrome or autoimmune multiorganopathy?

Authors:  Vikram K Mahajan; Vikas Sharma; Pushpinder S Chauhan; Karaninder S Mehta; Anju Lath Sharma; C Abhinav; Gayatri Khatri; Neel Prabha; Saurabh Sharma; Muninder Negi
Journal:  Case Rep Dermatol Med       Date:  2012-12-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.